Daewoong enters agreement with Medivir for MIV-210, hepatitis B and HIV therapy
Published: 2010-03-25 06:58:00
Updated: 2010-03-25 06:58:00
Daewoong Pharm announced on March 22 that it has signed an exclusive license and supply agreement with Medivir AB, a Sweden based pharmaceutical company, for a novel hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210).
Under the terms of the agreement, Daewoong ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
